|
|
| (4 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| {{CMG}}
| | #REDIRECT [[Fondaparinux#Adverse Reactions]] |
|
| |
|
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying possible adverse events and for approximating rates.
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| The data described below reflect exposure in 8,877 patients randomized to Arixtra Injection in controlled trials of hip fracture, hip replacement, major knee, or abdominal surgeries, and DVT and PE treatment. Patients received Arixtra primarily in 2 large peri-operative dose-response trials (n = 989), 4 active-controlled peri-operative trials with enoxaparin sodium (n = 3,616), and an extended prophylaxis trial (n = 327), an active-controlled trial with dalteparin sodium (n = 1,425), a dose-response trial in DVT treatment (n = 111), an active-controlled trial with enoxaparin sodium in DVT treatment (n = 1,091), and an active-controlled trial with heparin in PE treatment (n = 1,092).
| | [[Category: Anticoagulants]] |
| | |
| ===Hemorrhage===
| |
| | |
| During administration of Arixtra, the most common adverse reactions were bleeding complications.
| |